Lv12
38 积分 2024-10-10 加入
Non-small-cell lung cancer
1天前
已完结
Non-small-cell lung cancer
1天前
已完结
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
8天前
已完结
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
8天前
已完结
Targeted Bias: The Next Swing at IL2 Therapy
12天前
已完结
皖公网安备34019202002308
